Favorable mortality profile of naltrexone implants for opiate addiction

Journal of Addictive Diseases

Volumn 29, Issue 1, 2010, Pages 30-50

  Reece, Albert Stuart ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Buprenorphine; Heroin; Naltrexone depot; Naltrexone implant; Opiate; Registry controlled

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; NALTREXONE; DRUG DOSAGE FORM; DRUG IMPLANT; NARCOTIC ANTAGONIST;

ADULT; AGE DISTRIBUTION; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG IMPLANT; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPIATE ADDICTION; SEX DIFFERENCE; SURVIVAL RATE; AGE; COMPARATIVE STUDY; DRUG DOSAGE FORM; EPIDEMIOLOGY; OPIOID-RELATED DISORDERS; ORAL DRUG ADMINISTRATION; REGISTER; RISK FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AUSTRALIA; BUPRENORPHINE; DOSAGE FORMS; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; REGISTRIES; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 77951221353     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550880903435988     Document Type: Article

References (134)

1. Darke S, Degenhardt L, Mattick R. Mortality amongst illicit drug users: epidemiology, causes and intervention. Sydney: Cambridge University Press, 2007.
2. Gronbladh L, Gunne L. Methadone-assisted rehabilitation of Swedish heroin addicts. Drug Alcohol Depend 1989; 24:31-37 (Pubitemid 19167726)
3. Hulse GK, English DR, Milne E, Holman CD. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999; 94:221-229 (Pubitemid 29068963)
4. Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts' risk of fatal heroin overdose. Subst Use Misuse 1996; 31:177-196 (Pubitemid 26094982)
5. Caplehorn JR, Drummer OH. Mortality associated with New SouthWales methadone programs in 1994: lives lost and saved. Med J Aust 1999; 170:104-109 (Pubitemid 29060340)
6. Dyer KR, White JM. Patterns of symptom complaints in methadone maintenance patients. Addiction 1997; 92:1445-1455 (Pubitemid 27499557)
7. Reece AS. Dentition of addiction in Queensland: poor dental status and major contributing drugs. Aust Dent J 2007; 52:144-149
8. Carter EF. Dental implications of narcotic addiction. Aust Dent J 1978; 23:308-310
9. Fan J, Hser YI, Herbeck D. Tooth retention, tooth loss and use of dental care among long-term narcotics abusers. Subst Abus 2006; 27:25-32. (Pubitemid 44532931)
10. Schreiber S, Peles E, Adelson M. Association between improvement in depression, reduced benzodiazepine (BDZ) abuse, and increased psychotropicmedication use in methadone maintenance treatment (MMT) patients. Drug Alcohol Depend 2008; 92:79-85. (Pubitemid 350213240)
11. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001; 62:111-123 (Pubitemid 32195501)
12. Suzuki S, Carlos MP, Chuang LF, Torres JV, Doi RH, Chuang RY. Methadone induces CCR5 and promotes AIDS virus infection. FEBS Lett 2002; 519:173-177 (Pubitemid 34522013)
13. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol 2006; 1:280-295
14. Pillai R, Nair BS,Watson RR. AIDS, drugs of abuse and the immune system: a complex immunotoxicological network. Arch Toxicol 1991; 65:609-617
15. Li Y, Wang X, Tian S, Guo CJ, Douglas SD, Ho WZ. Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis 2002; 185: 118-122 (Pubitemid 34043026)
16. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007; 153:891-899 (Pubitemid 46809861)
17. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167:2469-2475
18. Ehret GB, Desmeules JA, Broers B. Methadoneassociated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Drug Saf 2007; 6:289-303. (Pubitemid 46767636)
19. Darke S, Kaye S, Duflou J. Systemic disease among cases of fatal opioid toxicity. Addiction 2006; 101:1299-1305 (Pubitemid 44199521)
20. Hser YI, Gelberg L, Hoffman V, Grella CE, McCarthy W, Anglin MD. Health conditions among aging narcotics addicts: medical examination results. J Behav Med 2004; 27:607-622 (Pubitemid 41223582)
21. Howard AA, Floris-Moore M, Arnsten JH, Santoro N, FleischerN,LoY, Schoenbaum EE. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis 2005; 40:1492-1499 (Pubitemid 40628638)
22. Szpanowska-Wohn A, Kolarzyk E, Pach D, Targosz D. [Nutritional status of opiate-dependent persons before and during methadone maintenance therapy]. Przegl Lek 2004; 61:339-344
23. Howard AA, Floris-Moore M, Lo Y, Arnsten JH, Fleischer N, Klein RS. Abnormal glucose metabolism among older men with or at risk of HIV infection. HIV Med 2006; 7:389-396 (Pubitemid 44123250)
24. Cooper OB, Brown TT, Dobs AS. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis 2003; 37(Suppl 2):S132-6.
25. Sadeghian S, Darvish S, Davoodi G, Salarifar M, Mahmoodian M, Fallah N, Karimi AA. The association of opium with coronary artery disease. Eur J Cardiovasc Prev Rehabil 2007; 14:715-717 (Pubitemid 47556410)
26. Rosen D, Smith ML, Reynolds CF 3rd. The prevalence of mental and physical health disorders among older methadone patients.AmJ Geriatr Psychiatry 2008; 16:488-497
27. Hser YI,McCarthyWJ, Anglin MD. Tobacco use as a distal predictor of mortality among long-term narcotics addicts. Prev Med 1994; 23:61-69
28. Yang JC, Huang D, Hser YI. Long-term morbidity and mortality among a sample of cocaine-dependent black and white veterans. J Urban Health 2006; 83:926-940 (Pubitemid 44310358)
29. Gottshcalk LA, McGuire FL, Heiser JF, Dinovo EC, Birch H. Drug abuse deaths in nine cities: A survey report. In: National Institute of Drug Abuse Ed, Vol.29, NIDA Research Monograph. Bethesda,Maryland, USA: National Institutes of Health, 1979:1-189.
30. Arnold-Reed DE, Hulse GK, Hansson RC, Murray SD, O'Neil G, Basso MR, Holman CD. Blood morphine levels in naltrexone-exposed compared to non-naltrexoneexposed fatal heroin overdoses. Addict Biol 2003; 8: 343-350 (Pubitemid 37215072)
31. Brunton LL, Lazo JS, Parker KL. Goodman and Gilman's the Pharmacologic Basis of Therapeutics, Vol.1. New York: McGraw Hill, 2006:2021.
32. Reece AS. Chronic hepatitis as an important contributor to the immunosenescence of parenteral drug addiction. Addiction Biology 2008; 14:214-226.
33. Reece AS. Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers. Immun Ageing 2007; 4:6-15.
34. Salvioli S, Capri M, Valensin S, Tieri P, Monti D, Ottaviani E, Franceschi C. Inflamm-aging, cytokines and aging: state of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology. Curr Pharm Des 2006; 12:3161-3171 (Pubitemid 44227576)
35. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908:244-254 (Pubitemid 30462008)
36. Boren E, Gershwin ME. Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev 2004; 3:401-406 (Pubitemid 38993363)
37. Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Lofgren S, Nilsson BO, Ernerudh J, Pawelec G, Johansson B. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci 2005; 60:556-565 (Pubitemid 40847916)
38. Boon NA, Colledge NR, Walker BR, Hunter AA. Davidson's principles and practice of medicine. New York: Churchill Livingstone, 2006.
39. Fauci AS, Braunwald E, Kapser DL, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine, 17th Edition, Vol.1. New York: McGraw Hill, 2008:2754.
40. OchshornM, BodnerG,NovickDM, Kreek MJ. The effect of methadone in vitro on natural killer (NK) activity. NIDA Res Monogr 1989; 95:522-523 (Pubitemid 20347334)
41. Novick DM, Ochshorn M, Ghali V, Croxson TS, Mercer WD, Chiorazzi N, Kreek MJ. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J Pharmacol Exp Ther 1989; 250:606-610 (Pubitemid 19216146)
42. Bruce-Keller AJ, Turchan-Cholewo J, Smart EJ, Geurin T, Chauhan A, Reid R, Xu R, Nath A, Knapp PE, Hauser KF. Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia 2008; 56:1414-1427
43. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35:501-516
44. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54:713-720 (Pubitemid 27344098)
45. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53:401-407 (Pubitemid 26149228)
46. CarrieriMP, Amass L, Lucas GM,VlahovD,Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis 2006; 43(Suppl 4):S197-215. (Pubitemid 44901888)
47. Johnson RE, Strain EC, Amass L. Buprenorphine: howto use it right.DrugAlcohol Depend 2003; 70:S59-77. (Pubitemid 36556061)
48. Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. Am J Addict 2004; 13(Suppl 1):S17-28. (Pubitemid 38585688)
49. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001; 285:45. (Pubitemid 32042714)
50. Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104:73-77
51. Ho RC, Ho EC, Tan CH, Mak A. Pulmonary hypertension in first episode infective endocarditis among intravenous buprenorphine users: case report. Am J Drug Alcohol Abuse 2009; 35:199-202.
52. Ho RC, Ho EC, Mak A. Cutaneous complications among i.v. buprenorphine users. J Dermatol 2009; 36: 22-29
53. Kacinko SL, Jones HE, Johnson RE, Choo RE, HuestisMA. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther 2008; 84:604-612
54. Pettinati HM, Kampman KM, Lynch KG, Xie H, Dackis C, Rabinowitz AR, O'Brien CP. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav 2008; 33:651-667
55. Bostwick JM, Bucci JA. Internet sex addiction treated with naltrexone. Mayo Clin Proc 2008; 83:226-230
56. Dannon PN, Lowengrub K, Musin E, Gonopolsky Y, Kotler M. 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. J Clin Psychopharmacol 2007; 27:620-624 (Pubitemid 351339450)
57. McCann DJ. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders. Clin Pharmacol Ther 2008; 83:627-630 (Pubitemid 351417068)
58. Gerra G, Fantoma A, Zaimovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol 2006; 20:806-814 (Pubitemid 44622745)
59. Hollister LE. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Arch Gen Psychiatry 1978; 35:335-340
60. Brewer C, Streel E. Learning the language of abstinence in addiction treatment: some similarities between relapse-prevention with disulfiram, naltrexone, and other pharmacological antagonists and intensive "immersion" methods of foreign language teaching. Subst Abus 2003; 24:157-173 (Pubitemid 37169087)
61. Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy 2007; 2: 35-49.
62. Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, Egorova VY, Didenko TY, Romanova TN, Ivanova EB, Bespalov AY, Verbitskaya EV, Neznanov NG, Grinenko AY, O'Brien CP, Woody GE. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat 2004; 26:285-294 (Pubitemid 38759145)
63. Carreno JE, Bobes J, Brewer C, Alvarez CE, San Narciso GI, Bascaran MT, Sanchez del Rio J. 24-hour opiate detoxification and antagonist induction at home-the 'Asturian method': a report on 1368 procedures. Addict Biol 2002; 7:243-250 (Pubitemid 34492961)
64. Rawson RA, Tennant FS Jr. Five-year follow-up of opiate addicts with naltrexone and behavior therapy. NIDA Res Monogr 1984; 49:289-295
65. Digiusto E, Shakeshaft A, Ritter A, O'Brien S, Mattick RP. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 2004; 99:450-460 (Pubitemid 38496661)
66. Miotto K, McCann MJ, Rawson RA, Frosch D, Ling W. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug Alcohol Depend 1997; 45:131-134 (Pubitemid 27246414)
67. Landabaso MA, Iraurgi I, Jimenez-Lerma JM, Sanz J, Fernadez de Corres B, Araluce K, Calle R, Gutierrez- Fraile M. A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts. Addiction 1998; 93:739-744 (Pubitemid 28230605)
68. Miotto K, McCann M, Basch J, Rawson R, Ling W. Naltrexone and dysphoria: fact or myth?AmJAddict 2002; 11:151-160 (Pubitemid 34538652)
69. Ngo HT, Tait RJ, Arnold-Reed DE, Hulse GK. Mental health outcomes following naltrexone implant treatment for heroin-dependence. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:605-612 (Pubitemid 46467038)
70. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 2002; 38:351-376 (Pubitemid 34219111)
71. Anderson JE.Arole for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. Mol Biol Cell 2000; 11:1859-1874
72. Chabi B, Ljubicic V,Menzies KJ, Huang JH, Saleem A, Hood DA. Mitochondrial function and apoptotic susceptibility in aging skeletal muscle. Aging Cell 2008; 7: 2-12.
73. Edelberg JM, Ballard VL. Stem Cell Review Series: Regulating highly potent stem cells in aging: environmental influences on plasticity. Aging Cell 2008; 7:599-604.
74. Wang X, Douglas SD, Peng JS, Metzger DS, O'Brien CP, Zhang T, HoWZ. Naltrexone inhibits alcoholmediated enhancement of HIV infection of T lymphocytes. J Leukoc Biol 2006; 79:1166-1172 (Pubitemid 44835550)
75. Gekker G, Lokensgard JR, Peterson PK. Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures. Drug Alcohol Depend 2001; 64:257-263 (Pubitemid 32973869)
76. Jeffrey GP, MacQuillan G, Chua F, Galhenage S, Bull J, Young E, Hulse G, O'Neil G. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 2007; 45:111-117 (Pubitemid 46144370)
77. Gibson AE, Degenhardt LJ, Hall WD. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust 2007; 186:152-153 (Pubitemid 46322369)
78. Khong E, ChoyW. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust 2007; 187:56. (Pubitemid 47082745)
79. Brewer CL. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust 2007; 187:55. (Pubitemid 47082742)
80. Hulse GK, Tait RJ. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust 2007; 187:54. (Pubitemid 47082740)
81. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, KampmanK, Dackis C, O'BrienCP. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63:210-218 (Pubitemid 43213883)
82. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot naltrexone: longlasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl) 2002; 159:351-360
83. Comer SD, Sullivan MA, Hulse GK. Sustainedrelease naltrexone: novel treatment for opioid dependence. Expert Opin Investig Drugs 2007; 16:1285-1294 (Pubitemid 47317017)
84. Sullivan MA, Garawi F, Bisaga A, Comer SD, Carpenter K, Raby WN, Anen SJ, Brooks AC, Jiang H, Akerele E,Nunes EV. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007; 91:289-292 (Pubitemid 47542538)
85. Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology (Berl) 2006; 189:37-46.
86. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson RC. Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants. Addict Biol 2004; 9: 67-72. (Pubitemid 38608488)
87. Hulse GK, O'Neil G, Arnold-Reed DE. Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user. Int J Gynaecol Obstet 2004; 85:170-171 (Pubitemid 38510235)
88. Hulse GK, O'Neil G, Hatton M, Paech MJ. Use of oral and implantable naltrexone in the management of the opioid impaired physician. Anaesth Intensive Care 2003; 31:196-201. (Pubitemid 36503835)
89. Hulse GK, O'Neill G. A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user. Aust N Z J Obstet Gynaecol 2002; 42:93-94 (Pubitemid 34173100)
90. Hulse GK, O'Neill G, Pereira C, Brewer C. Obstetric and neonatal outcomes associated with maternal naltrexone exposure. Aust N Z J Obstet Gynaecol 2001; 41: 424-428 (Pubitemid 33100682)
91. Tait RJ, NgoHT, Hulse GK. Mortality in heroin users 3 years after naltrexone implant ormethadone maintenance treatment. J Subst Abuse Treat 2008; 35:116-124
92. Ngo HT, Arnold-Reed DE, Hansson RC, Tait RJ, Hulse GK. Blood naltrexone levels over time following naltrexone implant. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:23-28
93. Hulse GK, Arnold-Reed DE,Ngo H, Reece AS. Naltrexone Implants in the Treatment of Heroin Addiction. In: McKenna CR. Ed. Trends in Substance Abuse Research, Vol.1. New York: Nova, 2007:71-88.
94. Hulse GK, Tait RJ, Comer SD, Sullivan MA, Jacobs IG, Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend 2005; 79: 351-357 (Pubitemid 41127163)
95. Hulse GK, Tait RJ. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users. Addict Biol 2003; 8:337-342
96. Degenhardt L, Gibson A,Mattick RP, HallW. Depot naltrexone use for opioid dependence in Australia: largescale use of an unregistered medication in the absence of data on safety and efficacy. Drug Alcohol Rev 2008; 27: 1-3.
97. Verebey K. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics. NIDA Res Monogr 1981; 28:147-158 (Pubitemid 12235218)
98. Kleber HD. Naltrexone. J Subst Abuse Treat 1985; 2:117-122
99. Kleber HD,Kosten TR, Gaspari J, Topazian M. Nontolerance to the opioid antagonism of naltrexone. Biol Psychiatry 1985; 20:66-72. (Pubitemid 16051968)
100. Gonzalez JP, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35:192-213.
101. Resnick RB, Volavka J, Freedman AM, Thomas M. Studies of EN-1639A (naltrexone): a new narcotic antagonist. Am J Psychiatry 1974; 131:646-650
102. Kunoe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen O, Waal H. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 2009; 194:541-546
103. Reece, AS. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine. J Subst Abuse Treat 2009; 37:256-265
104. Lintzeris N, Clark N, Winstock A, Dunlop A, Muhleisen P, Gowing L, Ali R, Bell J, Quigley A, Mattick RP, Monheit B, White J. National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Opioid Dependence: Abbreviated. In: Ageing, FDoHa Ed, Vol.1. Canberra: Australian Government Publishing Service, 2006:1-22.
105. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson R, O'Neil P. Blood naltrexone and 6-betanaltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol 2004; 9:59-65. (Pubitemid 38608487)
106. Breslow NE, Day NE. The design and analysis of cohort studies. Lyon: International Agency for Research on Cancer, 1987.
107. Stewart LM, Henderson CJ, Hobbs MS, Ridout SC, KnuimanMW. Risk of death in prisoners after release from jail. Aust N Z J Public Health 2004; 28:32-36
108. Australian Bureau of Statistics. Deaths-Australia. In: Australian Bureau of Statistics. 1. Canberra: Australian Government Publishing Service, 2007.
109. Australian Bureau of Statistics. ABS website. http://www.abs.gov.au/ AUSSTATS/abs@nsf/DetailsPage 3302.02008?Open Document Canberra: Australian Government Publishing Service, 2008.
110. Dunbar JL, TurncliffRZ, Hayes SC, Farrell CB. Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. J Stud Alcohol Drugs 2007; 68:862-870
111. Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res 2006; 30:480-490 (Pubitemid 43341354)
112. Dean RL, Todtenkopf MS, Deaver DR, Arastu MF, Dong N, Reitano K, O'Driscoll K, Kriksciukaite K, Gastfriend DR. Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone. Pharmacol Biochem Behav 2008; 89:515-522
113. Hamilton RJ, Olmedo RE, Shah S, Hung OL, Howland MA, Perrone J, Nelson LS, Lewin NL, Hoffman RS. Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Acad Emerg Med 2002; 9: 63-68 (Pubitemid 34049229)
114. Reece S. Rapid opioid detoxification in Australia. Acad Emerg Med 2002; 9:960-962
115. Darke S. Polydrug use and overdose: overthrowing old myths. Addiction 2003; 98:711. (Pubitemid 36688049)
116. Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health 2003; 80: 189-200. (Pubitemid 37486655)
117. Darke S, MattickRP, Degenhardt L. The ratio of nonfatal to fatal heroin overdose. Addiction 2003; 98:1169-1171
118. Darke S, Ross J, LynskeyM, TeessonM. Attempted suicide among entrants to three treatment modalities for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence and risk factors. Drug Alcohol Depend 2004; 73:1-10. (Pubitemid 37542473)
119. Darke S, Ross J, Williamson A, Mills KL, Havard A, Teesson M. Patterns and correlates of attempted suicide by heroin users over a 3-year period: findings from the Australian treatment outcome study. Drug Alcohol Depend 2007; 87:146-152 (Pubitemid 46215920)
120. Darke S, Williamson A, Ross J, Teesson M. Attempted suicide among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend 2005; 78:177-186 (Pubitemid 40544605)
121. Reece AS. Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers. Immunity and Ageing, 2007; 4:6.
122. Reece AS. Hair graying in substance addiction. Arch Dermatol 2007; 143:116-118
123. Reece AS, Davidson P. Deficit of circulating stem- progenitor cells in opiate addiction: a pilot study. Subst Abuse Treat Prev Policy 2007; 2:19.
124. Kim TW, Alford DP, Malabanan A, Holick MF, Samet JH. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend 2006; 85:258-262 (Pubitemid 44666285)
125. Wang M, Zhang J, Spinetti G, Jiang LQ, Monticone R, Zhao D, Cheng L, Krawczyk M, Talan M, Pintus G, Lakatta EG. Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol 2005; 167: 1429-1442 (Pubitemid 41541428)
126. Kirkpatrick B, Messias E, Harvey PD, Fernandez- Egea E, Bowie CR. Is schizophrenia a syndrome of accelerated aging? Schizophr Bull 2008; 34:1024-1032
127. Aldington S, Harwood M, Cox B, Weatherall M, Beckert L, Hansell A, Pritchard A, Robinson G, Beasley R. Cannabis use and risk of lung cancer: a case-control study. Eur Respir J 2008; 31:280-286 (Pubitemid 351288442)
128. Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, Hsu TC, Schantz SP. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 1999; 8: 1071-1078 (Pubitemid 30004904)
129. Sidney S,Quesenberry CP Jr, Friedman GD, Tekawa IS.Marijuana use and cancer incidence (California, United States). Cancer Causes Control 1997; 8:722-728 (Pubitemid 27404642)
130. Reece A. Lifetime prevalence of cervical neoplasia in addicted and medical patients. Aust N Z J Obstet Gynaecol 2007; 47:419-423 (Pubitemid 47433849)
131. Rao RE, Wojnicki FH, Coupland J, Ghosh S, Corwin RL. Baclofen, raclopride, and naltrexone differentially reduce solid fat emulsion intake under limited access conditions. Pharmacol Biochem Behav 2008; 89: 581-590
132. Reid LD. Endogenous opioid peptides and regulation of drinking and feeding. Am J Clin Nutr 1985; 42:1099-1132 (Pubitemid 16148064)
133. Reece AS. Experience of road and other trauma by the opiate dependent patient: a survey report. Subst Abuse Treat Prev Policy 2008; 3:10.
134. Reece AS. Chronology and patterns of psychiatric morbidity in substance dependent and medical patients. Australasian Psychiatry 2009; 17:170-171.